U.S. markets closed
  • S&P Futures

    3,697.75
    -11.25 (-0.30%)
     
  • Dow Futures

    29,597.00
    -72.00 (-0.24%)
     
  • Nasdaq Futures

    11,351.25
    -25.50 (-0.22%)
     
  • Russell 2000 Futures

    1,681.20
    -4.90 (-0.29%)
     
  • Crude Oil

    78.96
    +0.22 (+0.28%)
     
  • Gold

    1,648.30
    -7.30 (-0.44%)
     
  • Silver

    18.61
    -0.30 (-1.59%)
     
  • EUR/USD

    0.9662
    -0.0026 (-0.27%)
     
  • 10-Yr Bond

    3.6970
    -0.0110 (-0.30%)
     
  • Vix

    29.92
    +2.57 (+9.40%)
     
  • GBP/USD

    1.0566
    -0.0290 (-2.67%)
     
  • USD/JPY

    143.8360
    +0.5160 (+0.36%)
     
  • BTC-USD

    18,894.70
    -73.57 (-0.39%)
     
  • CMC Crypto 200

    433.90
    -10.63 (-2.39%)
     
  • FTSE 100

    7,018.60
    -140.92 (-1.97%)
     
  • Nikkei 225

    26,603.96
    -549.87 (-2.03%)
     

Smiths Acquisition Weighs On ICU Medical's Profitability, Shares Fall

·1 min read
  • ICU Medical Inc (NASDAQ: ICUI) reported Q2 sales of $561 million, up 75% Y/Y, due to Smiths Medical's acquisition, and missing the consensus of $566.47 million.

  • Adjusted EPS fell from $1.88 to $1.37, missing the consensus of $1.86.

  • Guidance: ICU Medical forecasts FY22 adjusted EBITDA of $350-$370 million, down from a prior range of $450-$500 million, and adjusted EPS of $6.20 - $6.80, compared to $9.00 - $10.50 expected earlier.

  • Raymond James writes that while legacy ICUI continues to perform well (organic revenue growth was +6% y/y in 2Q), inflationary pressures and sluggish Smiths sales continue to weigh on profitability.

  • The 2022 guidance came in below estimates, as the Smiths acquisition has become a bigger struggle.

  • The analyst believes that the commentary around recent trends was encouraging, and the implied 4Q guidance gives some hope that '23 should be better.

  • The analyst has lowered the price target from $208 to $190 with an Outperform rating unchanged.

  • Price Action: ICUI shares are down 10.7% at $168.07 during the market session on the last check Tuesday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.